Navigation Links
Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Date:11/11/2009

cs; the risk that the FDA may interpret data differently than we do, and the FDA's actions with respect to our BLA and whether the FDA determines to convene an advisory committee to review the BLA; progress on the commercialization efforts for PROVENGE, including the expansion of Dendreon's manufacturing capacity and other necessary infrastructure; success in the hiring of additional personnel to support business growth and expansion; the outcome of any pre-approval inspection of Dendreon's expanded manufacturing facility; our dependence on the efforts of third parties; our reliance on intellectual property protection; and requisite receipt of FDA licensure for marketing of PROVENGE and the risk that additional capital could be needed in the future to fund additional required clinical trials or for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

                    DENDREON CORPORATION
            CONSOLIDATED STATEMENTS OF OPERATIONS
           (in thousands, except per share amounts)

                                 Three months ended       Nine months ended
                                    September 30,            September 30,
                                 ------------------       -----------------
                          
'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Completes Submission of Biologics License Application for PROVENGE
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
5. Dendreon Reports Second Quarter 2009 Financial Results
6. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
7. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
10. Dendreon Announces Closing of Common Stock Offering
11. Dendreon Announces Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- The 12th Cold Chain GDP & Temperature Management ... at the John B. Hynes Convention Center. The remarkable ... for a weeklong conference attracting industry executives from around ... to cover the industry,s most pressing topics, with an ... range products, GDP compliance requirements and supply chain integrity. ...
(Date:9/29/2014)...  Perrigo Company plc (NYSE: PRGO ... a portfolio of preclinical research assets, which it ... Corporation plc, to drug discovery and development company, ... will receive an upfront payment in addition to ... future sales derived from the portfolio. ...
(Date:9/29/2014)... Sept. 29, 2014  Xcenda, the strategic consulting ... pharmaceutical sourcing and distribution service companies, recently conducted ... This research was analyzed in an economic model ... with an increase in life years and a ... population-level coffee consumption across the United ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today ... highly effective new tool for organic growers. SUPPRESS™ ... contact herbicide for post-emergent, non-selective weed control for ... The formulation is an emulsifiable concentrate that has ... (OMRI) for use in organic food production. , ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... RANCHO CORDOVA, Calif., Aug. 30 ThermoGenesis Corp. (Nasdaq: ... services that process and store adult stem cells, said today ... Ltd. (HealthBanks). HealthBanks, which operates cord blood banks ... a total of 20 BioArchives and a storage capacity for ...
... -- PARIS, August 30, 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Bioheart, Inc., (OTC Bulletin Board: BHRT ) ... with stem cell therapy on the first two congestive ... Angeles Tijuana through its Center of Excellence, Regenerative Medicine ... an agreement to establish a Center of Excellence for ...
Cached Biology Technology:ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market 2ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market 3ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 2ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 3ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 4ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 5ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 6ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty 7Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 2Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 3Bioheart Reports Significant Improvements in Heart Failure Patients from Center of Excellence Program 4
(Date:9/29/2014)... 210 million years ago when the supercontinent of Pangea was ... nearly everything, entirely different kinds of reptiles called phytosaurs and ... It was widely believed the two top predators didn,t interact ... the latter ruled the land. But those ideas are changing, ... In a paper published online in September in the German ...
(Date:9/29/2014)... a combination of a real-time feedback system together with ... resulted in a reduction of 37% in energy consumption ... kWh, which is equivalent to a reduction of 713.71 ... , In contrast, another eight halls, exposed only to ... in saw a 3.5% reduction in energy consumption. , ...
(Date:9/29/2014)... 2014 Growing Demand From ... Increasing Security Concerns Continue to Propel Biometrics Market ... is one of the fastest growing biometrics ... systems, majorly in various government projects such as ... based biometrics dominates the country,s biometrics market, with ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... Boston, MA - Tiny particles only billionths of a meter ... human haircould offer big hope in a small package to the ... everything from jewelry to coins and cell phones, say scientists at ... issue of Nature Nanotechnology, the team will report a ...
... the largest study of its kind, researchers from a consortium ... linked to late-onset Alzheimer,s disease. Each of these genes adds ... the disease, and together they offer a portal into the ... to determine who is at risk of developing the disease, ...
... Medicine researchers are part of a consortium that has identified ... a person developing Alzheimer,s disease later in life. The ... The consortium also contributed to the identification of a ... United States and Europe. "Mount Sinai has unique resources ...
Cached Biology News:Nanoparticles offer hope for common skin allergy 2Nanoparticles offer hope for common skin allergy 3Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 34 new genes identified for Alzheimer's disease risk 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: